• ABOUT US
    • TEAM
    • Advisors
  • Portfolio
    • FUND I
    • FUND II
    • EXITS
    •  
  • Investment Criteria
  • News
  • Contact

News

October 25, 2019
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

October 22, 2019
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

September 25, 2019
T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio

September 10, 2019
T2 Biosystems Awarded Breakthrough Technology Contract with Premier Inc.

August 16, 2019
T2 Biosystems Expands Access to its Innovative Rapid Diagnostic Technologies to Australia, Fiji and New Zealand

August 6, 2019
T2Bacteria Panel is the First and Only In-Vitro Diagnostic Test to Receive Approval for a New Technology Add-on Payment by CMS

August 1, 2019
I-Mab Biopharma And TRACON Pharmaceuticals Announce Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of The CD73 Antibody TJD5 In Patients With Advanced Solid Tumors

July 26, 2019
T2 Biosystems Expands Global Access to its Innovative Rapid Diagnostic Technologies

July 17, 2019
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia

July 10, 2019
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

July 2, 2019
TRACON Pharmaceuticals Provides Update On Phase 1/2 Trial Of TRC253 In Patients With Metastatic Castrate Resistant Prostate Cancer

© 2018 ArcusVentures. Powered by BlueSwitch